Terns Pharmaceuticals, Inc.
TERNDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831363
Terns Pharmaceuticals, Inc. was delisted in 2026; its insiders filed their last Form 4 on May 5, 2026; 317 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 317
- Q1 2026, +76 vs. previous quarter
- 13F value
- $6.56B
- Reported value at the end of Q1 2026
- Superinvestors holding
- 1
- At the end of Q1 2026
Superinvestors holding TERN, Q1 2026
1 superinvestor reports holding Terns Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
0.2%
Terns Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 321,905
- Value
- $17.0M
Latest insider trades
Open-market purchases and sales by Terns Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Kuriakose EmilChief Medical Officer | SSale | −942 | $52.75 | −$49.7K | −0.9%105.7K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Burroughs Amy L.Chief Executive Officer | SSale | −14.6K | $46.71 | −$681.2K | −4.8%289.0K after | 2 lots10b5-1 |
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | Burroughs Amy L.Chief Executive Officer | SSale | −14.6K | $39.20 | −$571.6K | −4.8%289.0K after | 3 lots10b5-1 |
| Jan 16, 2026 (view filing) | Jan 15 | 1 day | Burroughs Amy L.Chief Executive Officer | SSale | −68.7K | $37.08 | −$2.55M | −19.2%289.0K after | 2 lots10b5-1 |
| Jan 6, 2026 (view filing) | Jan 2 | 4 days | Kuriakose EmilChief Medical Officer | SSale | −1.16K | $38.57 | −$44.6K | −2.2%50.4K after | 2 lots |
| Jan 6, 2026 (view filing) | Jan 5 | 1 day | Burroughs Amy L.Chief Executive Officer | SSale | −71.3K | $38.10 | −$2.72M | −33.9%139.0K after | |
| Nov 5, 2025 (view filing) | Nov 4 | 1 day | Quigley Jill M.Director | SSale | −24.5K | $18.00 | −$441.4K | −100.0%0 after | 10b5-1 |
| Oct 2, 2025 (view filing) | Oct 1 | 1 day | Kuriakose EmilChief Medical Officer | SSale | −944 | $7.85 | −$7.41K | −1.8%51.5K after | |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Kuriakose EmilChief Medical Officer | SSale | −853 | $4.27 | −$3.64K | −1.6%52.5K after | |
| Jun 30, 2025 (view filing) | Jun 27 | 3 days | Gengos AndrewChief Financial Officer | PPurchase | +10.0K | $3.93 | +$39.3K | +66.7%25.0K after | 2 lots |
Top 10 13F holders, Q1 2026
The largest institutional positions in Terns Pharmaceuticals, Inc. at the end of Q1 2026; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,569,585 | $504.5M | 0.01% | +1,375,367+16.8% | Added |
| Morgan Stanley | 6,449,140 | $340.0M | 0.02% | −1,496,468−18.8% | Reduced |
| Avoro Capital Advisors LLC | 5,695,000 | $300.2M | 2.96% | +1,345,000+30.9% | Added |
| Vanguard Capital Management LLC | 4,355,482 | $229.6M | 0.01% | +4,355,482 | New |
| Holocene Advisors, LP | 4,115,828 | $217.0M | 0.53% | +1,340,335+48.3% | Added |
| Citadel Advisors LLC | 3,218,810 | $169.7M | 0.12% | +52,168+1.6% | Added |
| Millennium Management LLC | 3,011,558 | $158.8M | 0.12% | +2,024,252+205.0% | Added |
| HBK Investments L P | 2,950,000 | $155.5M | 1.96% | +2,950,000 | New |
| JPMorgan Chase & Co | 2,869,728 | $151.8M | 0.01% | +1,096,702+61.9% | Added |
| Lord, Abbett & Co. LLC | 2,812,938 | $148.3M | 0.48% | +100,539+3.7% | Added |